share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-KNIGHT THERAPEUTICS INC.(9.97%),KNIGHT THERAPEUTICS INTERNATIONAL S.A.(9.97%)

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-KNIGHT THERAPEUTICS INC.(9.97%),KNIGHT THERAPEUTICS INTERNATIONAL S.A.(9.97%)

SC 13G/A：超過5%持股股東披露文件(修正)-KNIGHT THERAPEUTICS INC.(9.97%),KNIGHT THERAPEUTICS INTERNATIONAL S.A.(9.97%)
美股sec公告 ·  05/08 07:21
牛牛AI助理已提取核心訊息
Knight Therapeutics Inc., a Canadian pharmaceutical company, and its subsidiary, Knight Therapeutics International S.A., based in Uruguay, have jointly filed an amended Schedule 13G/A with the SEC, disclosing a significant stake in 60 Degrees Pharmaceuticals. The filing, dated May 3, 2024, indicates that Knight Therapeutics Inc. has transferred 1,153,897 shares of common stock from its subsidiary, resulting in direct beneficial ownership of 9.97% of 60 Degrees Pharmaceuticals' issued and outstanding shares as of April 1, 2024. The shares were previously held directly by Knight Therapeutics International S.A. The filing asserts that the shares are not intended for the purpose of changing or influencing the control of 60 Degrees Pharmaceuticals, nor in connection with any transaction having such purpose or effect.
Knight Therapeutics Inc., a Canadian pharmaceutical company, and its subsidiary, Knight Therapeutics International S.A., based in Uruguay, have jointly filed an amended Schedule 13G/A with the SEC, disclosing a significant stake in 60 Degrees Pharmaceuticals. The filing, dated May 3, 2024, indicates that Knight Therapeutics Inc. has transferred 1,153,897 shares of common stock from its subsidiary, resulting in direct beneficial ownership of 9.97% of 60 Degrees Pharmaceuticals' issued and outstanding shares as of April 1, 2024. The shares were previously held directly by Knight Therapeutics International S.A. The filing asserts that the shares are not intended for the purpose of changing or influencing the control of 60 Degrees Pharmaceuticals, nor in connection with any transaction having such purpose or effect.
加拿大製藥公司Knight Therapeutics Inc.及其位於烏拉圭的子公司Knight Therapeutics International S.A. 共同向美國證券交易委員會提交了經修訂的附表13G/A，披露了60度製藥的大量股份。這份日期爲2024年5月3日的文件顯示，Knight Therapeutics Inc.已從其子公司轉讓了1,153,897股普通股，截至2024年4月1日，60度製藥已發行和流通股票的9.97％的直接實益所有權。這些股票此前由Knight Therapeutics International S.A直接持有。該文件稱，這些股票的目的不是改變或影響60度製藥的控制權，也不是與任何具有此類目的或效果的交易有關。
加拿大製藥公司Knight Therapeutics Inc.及其位於烏拉圭的子公司Knight Therapeutics International S.A. 共同向美國證券交易委員會提交了經修訂的附表13G/A，披露了60度製藥的大量股份。這份日期爲2024年5月3日的文件顯示，Knight Therapeutics Inc.已從其子公司轉讓了1,153,897股普通股，截至2024年4月1日，60度製藥已發行和流通股票的9.97％的直接實益所有權。這些股票此前由Knight Therapeutics International S.A直接持有。該文件稱，這些股票的目的不是改變或影響60度製藥的控制權，也不是與任何具有此類目的或效果的交易有關。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。